

# Roberto Cauda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3112859/publications.pdf>

Version: 2024-02-01

220  
papers

12,621  
citations

28242

55  
h-index

29127

104  
g-index

223  
all docs

223  
docs citations

223  
times ranked

16883  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of chloroquine on viral infections: an old drug against today's diseases. <i>Lancet Infectious Diseases</i> , The, 2003, 3, 722-727.	4.6	1,022
2	Predictors of Mortality in Bloodstream Infections Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> : Importance of Combination Therapy. <i>Clinical Infectious Diseases</i> , 2012, 55, 943-950.	2.9	855
3	New insights into the antiviral effects of chloroquine. <i>Lancet Infectious Diseases</i> , The, 2006, 6, 67-69.	4.6	458
4	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre study. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, 2133-2143.	1.3	434
5	Predictors of Mortality in Patients with Bloodstream Infections Caused by Extended-Spectrum- $\beta$ -Lactamase-Producing Enterobacteriaceae : Importance of Inadequate Initial Antimicrobial Treatment. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 1987-1994.	1.4	382
6	Does antibiotic exposure increase the risk of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) isolation? A systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 61, 26-38.	1.3	340
7	Biofilm Production by <i>Candida</i> Species and Inadequate Antifungal Therapy as Predictors of Mortality for Patients with Candidemia. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1843-1850.	1.8	300
8	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by <i>Klebsiella pneumoniae</i> Carbapenemase-producing <i>K. pneumoniae</i> . <i>Clinical Infectious Diseases</i> , 2019, 68, 355-364.	2.9	265
9	Bloodstream Infections Caused by Extended-Spectrum- $\beta$ -Lactamase-Producing <i>Klebsiella pneumoniae</i> : Risk Factors, Molecular Epidemiology, and Clinical Outcome. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 498-504.	1.4	243
10	Evolutionary analysis of SARS-CoV-2: how mutation of Non-Structural Protein 6 (NSP6) could affect viral autophagy. <i>Journal of Infection</i> , 2020, 81, e24-e27.	1.7	211
11	In Vitro and In Vivo Anticandidal Activity of Human Immunodeficiency Virus Protease Inhibitors. <i>Journal of Infectious Diseases</i> , 1999, 180, 448-453.	1.9	205
12	Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). <i>Aids</i> , 2002, 16, 369-379.	1.0	189
13	Costs of Bloodstream Infections Caused by <i>Escherichia coli</i> and Influence of Extended-Spectrum- $\beta$ -Lactamase Production and Inadequate Initial Antibiotic Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 4085-4091.	1.4	185
14	Improving empirical antibiotic treatment using TREAT, a computerized decision support system: cluster randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2006, 58, 1238-1245.	1.3	181
15	Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. <i>Aids</i> , 2001, 15, 1483-1491.	1.0	175
16	Risk Factors and Outcomes of Candidemia Caused by Biofilm-Forming Isolates in a Tertiary Care Hospital. <i>PLoS ONE</i> , 2012, 7, e33705.	1.1	170
17	Benefit of Appropriate Empirical Antibiotic Treatment: Thirty-day Mortality and Duration of Hospital Stay. <i>American Journal of Medicine</i> , 2006, 119, 970-976.	0.6	168
18	Incidence and clinical impact of extended-spectrum- $\beta$ -lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by <i>Escherichia coli</i> in patients with hematological malignancies. <i>Journal of Infection</i> , 2009, 58, 299-307.	1.7	144

#	ARTICLE	IF	CITATIONS
19	Candida and candidiasis in HIV-infected patients. <i>Aids</i> , 2012, 26, 1457-1472.	1.0	138
20	Identifying Patients Harboring Extended-Spectrum- $\beta$ -Lactamase-Producing Enterobacteriaceae on Hospital Admission: Derivation and Validation of a Scoring System. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3485-3490.	1.4	137
21	Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1899-1913.	1.1	137
22	Metallo- $\beta$ -lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. <i>International Journal of Antimicrobial Agents</i> , 2007, 29, 380-388.	1.1	134
23	HIV infection, HAART, and endothelial adhesion molecules: current perspectives. <i>Lancet Infectious Diseases</i> , 2004, 4, 213-222.	4.6	133
24	Ceftazidime-Avibactam Use for <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. <i>Clinical Infectious Diseases</i> , 2021, 73, 1664-1676.	2.9	130
25	Antibiotic Usage and Risk of Colonization and Infection with Antibiotic-Resistant Bacteria: a Hospital Population-Based Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 4264-4269.	1.4	127
26	Role of Protease Inhibitors in Preventing Recurrent Oral Candidosis in Patients With HIV Infection: A Prospective Case-Control Study. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 1999, 21, 20-25.	0.9	126
27	Reduced Rate of Diagnostic Positive Detection of JC Virus DNA in Cerebrospinal Fluid in Cases of Suspected Progressive Multifocal Leukoencephalopathy in the Era of Potent Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2005, 43, 4175-4177.	1.8	118
28	Rapid screening tests for methicillin-resistant <i>Staphylococcus aureus</i> at hospital admission: systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , 2009, 9, 546-554.	4.6	108
29	Anti-HIV Effects of Chloroquine. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 35, 223-232.	0.9	104
30	Incidence, risk factors, and predictors of outcome of candidemia. Survey in 2 Italian university hospitals. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 58, 325-331.	0.8	104
31	Bloodstream Infections Caused by Extended-Spectrum- $\beta$ -Lactamase-Producing <i>Escherichia coli</i> : Risk Factors for Inadequate Initial Antimicrobial Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3244-3252.	1.4	104
32	Off-label use of tocilizumab in patients with SARS-CoV-2 infection. <i>Journal of Medical Virology</i> , 2020, 92, 1787-1788.	2.5	102
33	Infection control and prevention measures to reduce the spread of vancomycin-resistant enterococci in hospitalized patients: a systematic review and meta-analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 1185-1192.	1.3	98
34	Prosthetic joint infection: Recent developments in diagnosis and management. <i>Journal of Infection</i> , 2010, 61, 443-448.	1.7	97
35	Neutrophil-to-lymphocyte ratio and clinical outcome in COVID-19: a report from the Italian front line. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106017.	1.1	97
36	Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study. <i>European Journal of Internal Medicine</i> , 2020, 82, 38-47.	1.0	88

#	ARTICLE	IF	CITATIONS
37	Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1054-1065.	1.8	87
38	Factors associated with mortality in bacteremic patients with hematologic malignancies. <i>Diagnostic Microbiology and Infectious Disease</i> , 2009, 64, 320-326.	0.8	82
39	Incidence of Bloodstream Infections, Length of Hospital Stay, and Survival in Patients With Recurrent <i>Clostridioides difficile</i> Infection Treated With Fecal Microbiota Transplantation or Antibiotics. <i>Annals of Internal Medicine</i> , 2019, 171, 695.	2.0	81
40	Antiretroviral Therapy with Protease Inhibitors Has an Early, Immune Reconstitution-Independent Beneficial Effect on <i>Candida</i> Virulence and Oral Candidiasis in Human Immunodeficiency Virus-Infected Subjects. <i>Journal of Infectious Diseases</i> , 2002, 185, 188-195.	1.9	79
41	SARS-CoV-2 B.1.617 Indian variants: Are electrostatic potential changes responsible for a higher transmission rate?. <i>Journal of Medical Virology</i> , 2021, 93, 6551-6556.	2.5	79
42	Multidrug-Resistant <i>Pseudomonas Aeruginosa</i> Bloodstream Infections: Analysis of Trends in Prevalence and Epidemiology. <i>Emerging Infectious Diseases</i> , 2002, 8, 220-221.	2.0	75
43	Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3514-3520.	1.4	75
44	Mitochondrial Membrane Hyperpolarization Hijacks Activated T Lymphocytes Toward the Apoptotic-Prone Phenotype: Homeostatic Mechanisms of HIV Protease Inhibitors. <i>Journal of Immunology</i> , 2003, 170, 6006-6015.	0.4	74
45	Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2012, 12, 296.	1.3	73
46	Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 109-117.	1.3	71
47	ESBL-producing multidrug-resistant <i>Providencia stuartii</i> infections in a university hospital. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 277-282.	1.3	68
48	Characteristics of <i>Staphylococcus aureus</i> Bacteraemia and Predictors of Early and Late Mortality. <i>PLoS ONE</i> , 2017, 12, e0170236.	1.1	67
49	Risk factors and predictors of mortality of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) bacteraemia in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2002, 50, 375-382.	1.3	66
50	Sarilumab use in severe SARS-CoV-2 pneumonia. <i>EClinicalMedicine</i> , 2020, 27, 100553.	3.2	66
51	Older age does not influence CD4 cell recovery in HIV-1 infected patients receiving Highly Active Anti Retroviral Therapy. <i>BMC Infectious Diseases</i> , 2004, 4, 46.	1.3	65
52	Potent anti-retroviral therapy with or without cidofovir for AIDS-associated progressive multifocal leukoencephalopathy: Extended follow-up of an observational study. <i>Journal of NeuroVirology</i> , 2001, 7, 364-368.	1.0	64
53	Evidence of a selective depletion of a CD16+ CD56+ CD8+ natural killer cell subset during HIV infection. <i>Cytometry</i> , 1995, 22, 10-15.	1.8	62
54	Treatment simplification to atazanavir/ritonavir+lamivudine versus maintenance of atazanavir/ritonavir+two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, dkw557.	1.3	62

#	ARTICLE	IF	CITATIONS
55	The electrostatic potential of the Omicron variant spike is higher than in Delta and Delta+plus variants: A hint to higher transmissibility?. <i>Journal of Medical Virology</i> , 2022, 94, 1277-1280.	2.5	60
56	Management of serious meticillin-resistant <i>Staphylococcus aureus</i> infections: what are the limits?. <i>International Journal of Antimicrobial Agents</i> , 2011, 37, 202-209.	1.1	59
57	Evaluation of the New VITEK 2 Extended-Spectrum Beta-Lactamase (ESBL) Test for Rapid Detection of ESBL Production in Enterobacteriaceae Isolates. <i>Journal of Clinical Microbiology</i> , 2006, 44, 3257-3262.	1.8	57
58	Analysis of the risk factors associated with the emergence of azole resistant oral candidosis in the course of HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 1996, 38, 691-699.	1.3	55
59	Older HIV-positive patients in the era of highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 128-131.	1.0	55
60	Detecting risk and predicting patient mortality in patients with extended-spectrum $\beta$ -lactamase-producing <i>Enterobacteriaceae</i> bloodstream infections. <i>Future Microbiology</i> , 2012, 7, 1173-1189.	1.0	55
61	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant <i>Klebsiella pneumoniae</i> bloodstream infection. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 244-248.	1.1	55
62	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 23, 145-151.	0.9	54
63	Increased soluble markers of endothelial dysfunction in HIV-positive patients under highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 765-768.	1.0	54
64	Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. <i>Cellular Immunology</i> , 1988, 115, 57-65.	1.4	52
65	Revised Central Nervous System Neuropenetration-Effectiveness Score is Associated with Cognitive Disorders in HIV-Infected Patients with Controlled Plasma Viraemia. <i>Antiviral Therapy</i> , 2013, 18, 153-160.	0.6	52
66	Multidrug-Resistant <i>Proteus mirabilis</i> Bloodstream Infections: Risk Factors and Outcomes. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3224-3231.	1.4	51
67	The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study. <i>BMC Infectious Diseases</i> , 2013, 13, 414.	1.3	51
68	Fungaemia caused by <i>Candida glabrata</i> with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1379-1385.	1.3	50
69	Patients with condyloma acuminatum exhibit decreased interleukin-2 and interferon gamma production and depressed natural killer activity. <i>Journal of Clinical Immunology</i> , 1987, 7, 304-311.	2.0	49
70	Glycopeptide Resistance among Coagulase-Negative <i>Staphylococci</i> that Cause Bacteremia: Epidemiological and Clinical Findings from a Case-Control Study. <i>Clinical Infectious Diseases</i> , 2001, 33, 1628-1635.	2.9	48
71	Prediction models to identify hospitalized patients at risk of being colonized or infected with multidrug-resistant <i>Acinetobacter baumannii</i> calcoaceticus complex. <i>Journal of Antimicrobial Chemotherapy</i> , 2008, 62, 1130-1137.	1.3	48
72	Risks and benefits of chloroquine use in anticancer strategies. <i>Lancet Oncology</i> , The, 2006, 7, 792-793.	5.1	46

#	ARTICLE	IF	CITATIONS
73	The Role of Oxidative Imbalance in Progression to AIDS: Effect of the Thiol Supplier N-Acetylcysteine. <i>AIDS Research and Human Retroviruses</i> , 1998, 14, 1589-1596.	0.5	45
74	Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment) <i>TJ ETQq0 0 0 rgBT /Overhock 10 Tt 50 692 Td</i>	1.3	45
75	Candidaemia in Patients with an Inserted Medical Device. <i>Drugs</i> , 2009, 69, 33-38.	4.9	43
76	Synthetic Peptides Corresponding to Sequences in HIV Envelope gp41 and gp120 Enhance In Vitro Production of Interleukin-1 and Tumor Necrosis Factor but Depress Production of Interferon- $\alpha$ , Interferon- $\beta$ and Interleukin-2. <i>Viral Immunology</i> , 1991, 4, 33-42.	0.6	41
77	Comparison of expression vectors in <i>Lactobacillus reuteri</i> strains. <i>FEMS Microbiology Letters</i> , 2010, 308, 8-15.	0.7	41
78	COVID-19 and intestinal inflammation: Role of fecal calprotectin. <i>Digestive and Liver Disease</i> , 2020, 52, 1231-1233.	0.4	40
79	RAAS inhibitors are not associated with mortality in COVID-19 patients: Findings from an observational multicenter study in Italy and a meta-analysis of 19 studies. <i>Vascular Pharmacology</i> , 2020, 135, 106805.	1.0	39
80	Mortality in patients with early- or late-onset candidaemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 927-935.	1.3	37
81	Efficacy and tolerability of dolutegravir and two nucleos(t)ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients. <i>Aids</i> , 2017, 31, 457-459.	1.0	36
82	Assessment of neurological manifestations in hospitalized patients with COVID-19. <i>European Journal of Neurology</i> , 2020, 27, 2322-2328.	1.7	36
83	Osteoarticular bacterial infections are rare in HIV-infected patients: 14 cases found among 4, 023 HIV-infected patients. <i>Acta Orthopaedica</i> , 1997, 68, 554-558.	1.4	35
84	Imatinib interferes with survival of multi drug resistant Kaposi's sarcoma cells. <i>FEBS Letters</i> , 2007, 581, 5897-5903.	1.3	35
85	Novel sensitive, specific and rapid pharmacogenomic test for the prediction of abacavir hypersensitivity reaction: HLA-B*57:01 detection by real-time PCR. <i>Pharmacogenomics</i> , 2011, 12, 567-576.	0.6	35
86	Antiretroviral Neuropenetrability Scores Better Correlate with Cognitive Performance of HIV-Infected Patients after Accounting for drug Susceptibility. <i>Antiviral Therapy</i> , 2015, 20, 441-447.	0.6	34
87	HIV-Protease Inhibitors Contribute to P-Glycoprotein Efflux Function Defect in Peripheral Blood Lymphocytes From HIV-Positive Patients Receiving HAART. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 27, 321-330.	0.9	33
88	Anti-retroviral therapy with protease inhibitors decreases virulence enzyme expression in vivo by <i>Candida albicans</i> without selection of avirulent fungus strains or decreasing their anti-mycotic susceptibility. <i>FEMS Immunology and Medical Microbiology</i> , 2004, 41, 27-34.	2.7	33
89	Deep Salvage With Amprenavir and Lopinavir/Ritonavir. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2004, 35, 359-366.	0.9	33
90	Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2050-2052.	1.3	33

#	ARTICLE	IF	CITATIONS
91	Cognitive reserve and neuropsychological functioning in older HIV-infected people. <i>Journal of NeuroVirology</i> , 2016, 22, 575-583.	1.0	33
92	Nosocomial Bloodstream Infections in HIV-Infected Patients: Attributable Mortality and Extension of Hospital Stay. <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1998, 19, 490-497.	0.3	32
93	Effect of Aging and Human Immunodeficiency Virus Infection on Cognitive Abilities. <i>Journal of the American Geriatrics Society</i> , 2012, 60, 2048-2055.	1.3	30
94	Prediction of specific pathogens in patients with sepsis: evaluation of TREAT, a computerized decision support system. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 59, 1204-1207.	1.3	29
95	Identification of Inhibitors of Drug-Resistant <i>Candida albicans</i> Strains from a Library of Bicyclic Peptidomimetic Compounds. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 2502-2509.	2.9	29
96	Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients. <i>Vaccine</i> , 2011, 29, 2836-2839.	1.7	29
97	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1955-1964.	1.3	29
98	Declining Prevalence of HIV-1 Drug Resistance in Treatment-Failing Patients: A Clinical Cohort Study. <i>Antiviral Therapy</i> , 2007, 12, 835-839.	0.6	29
99	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2055-2059.	1.3	28
100	Evidence for mutations in SARS-CoV-2 Italian isolates potentially affecting virus transmission. <i>Journal of Medical Virology</i> , 2020, 92, 2232-2237.	2.5	28
101	Gastric cryptosporidiosis complicating HIV infection: case report and review of the literature. <i>European Journal of Gastroenterology and Hepatology</i> , 1997, 9, 307-310.	0.8	26
102	Flow cytometric detection of perforin in normal human lymphocyte subpopulations defined by expression of activation/differentiation antigens. <i>Immunology Letters</i> , 1998, 60, 51-55.	1.1	26
103	HIV-Protease Inhibitors Contribute to P-Glycoprotein Efflux Function Defect in Peripheral Blood Lymphocytes From HIV-Positive Patients Receiving HAART. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2001, 27, 321-330.	0.9	25
104	Granulocyte colony-stimulating factor enhances the in vitro cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cell lines and primary blast cells. <i>Experimental Hematology</i> , 2006, 34, 54-65.	0.2	25
105	Lipid-lowering effect of tenofovir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 682-683.	1.3	24
106	Liability of Health Care Professionals and Institutions During COVID-19 Pandemic in Italy: Symposium Proceedings and Position Statement. <i>Journal of Patient Safety</i> , 2020, 16, e299-e302.	0.7	24
107	Sonographic Patterns of the Gallbladder in Acute Viral Hepatitis. <i>Journal of Clinical Ultrasound</i> , 1984, 12, 141-146.	0.4	23
108	Characterization of a novel human surface molecule selectively expressed by mature thymocytes, activated T cells and subsets of T cell lymphomas. <i>European Journal of Immunology</i> , 1999, 29, 2863-2874.	1.6	23



#	ARTICLE	IF	CITATIONS
109	Characterization of JC virus in cerebrospinal fluid from HIV-1 infected patients with progressive multifocal leukoencephalopathy: insights into viral pathogenesis and disease prognosis. <i>Journal of NeuroVirology</i> , 2007, 13, 338-346.	1.0	23
110	Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction. <i>Pharmacological Research</i> , 2011, 63, 249-253.	3.1	23
111	Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study). <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 34-45.	1.5	23
112	Highly Active Antiretroviral Therapy Decreases the Incidence of Bacteremia in Human Immunodeficiency Virus-Infected Individuals. <i>Clinical Infectious Diseases</i> , 1998, 27, 901-902.	2.9	21
113	Rate of CD4 <sup>+</sup> Cell Count Increase over Periods of Viral Load Suppression: Relationship with the Number of Previous Virological Failures. <i>Clinical Infectious Diseases</i> , 2010, 51, 456-464.	2.9	21
114	Immunogenicity and Safety of the 13-Valent Pneumococcal Conjugate Vaccine versus the 23-Valent Polysaccharide Vaccine in Unvaccinated HIV-Infected Adults: A Pilot, Prospective Controlled Study. <i>PLoS ONE</i> , 2016, 11, e0156523.	1.1	21
115	Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing <i>Klebsiella pneumoniae</i> infections: retrospective single-center case series. <i>Infection</i> , 2017, 45, 209-213.	2.3	21
116	Role of Polymorphonuclear Leukocytes in Infection by Retroviruses with Emphasis on the Human Immunodeficiency Virus. <i>Viral Immunology</i> , 1990, 3, 173-194.	0.6	20
117	In Vitro and In Vivo Modulation of MDR1/P-Glycoprotein in HIV-Infected Patients Administered Highly Active Antiretroviral Therapy and Liposomal Doxorubicin. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 30, 369-378.	0.9	20
118	Macrophage chemoattractant protein-1 levels in cerebrospinal fluid correlate with containment of JC virus and prognosis of acquired immunodeficiency syndrome-associated progressive multifocal leukoencephalopathy. <i>Journal of NeuroVirology</i> , 2005, 11, 219-224.	1.0	20
119	Antibiotic appropriateness and adherence to local guidelines in perioperative prophylaxis: results from an antimicrobial stewardship intervention. <i>Antimicrobial Resistance and Infection Control</i> , 2020, 9, 164.	1.5	20
120	Highly active antiretroviral therapy decreases the incidence of visceral leishmaniasis in HIV-infected individuals. <i>Aids</i> , 2000, 14, 2948-2949.	1.0	20
121	Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE). <i>Clinical Neuropsychologist</i> , 2016, 30, 1457-1468.	1.5	19
122	Impact of antibiotic stewardship on perioperative antimicrobial prophylaxis. <i>International Journal for Quality in Health Care</i> , 2016, 28, 502-507.	0.9	19
123	Lopinavir/Ritonavir or Efavirenz plus two Nucleoside Analogues as First-Line Antiretroviral Therapy: A Non-Randomized Comparison. <i>Antiviral Therapy</i> , 2006, 11, 609-618.	0.6	19
124	On the use of chloroquine for chikungunya. <i>Lancet Infectious Diseases</i> , The, 2007, 7, 633.	4.6	18
125	Azole Susceptibility Patterns and Genetic Relationship Among Oral <i>Candida</i> Strains Isolated in the Era of Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 38-44.	0.9	17
126	HIV proteinase inhibitors: do they really work against <i>Candida</i> in a clinical setting?. <i>Trends in Microbiology</i> , 2002, 10, 177-178.	3.5	17



#	ARTICLE	IF	CITATIONS
127	The Importance of Addressing Multidrug Resistance and Not Assuming Single-Drug Resistance in Case-Control Studies. <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 670-674.	1.0	17
128	Detection of <i>HLA-B*57:01</i> by real-time PCR: implementation into routine clinical practice and additional validation data. <i>Pharmacogenomics</i> , 2014, 15, 319-327.	0.6	17
129	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1949-1954.	1.3	17
130	Ethical Criteria for the Admission and Management of Patients in the ICU Under Conditions of Limited Medical Resources: A Shared International Proposal in View of the COVID-19 Pandemic. <i>Frontiers in Public Health</i> , 2020, 8, 284.	1.3	17
131	The value of electrostatic potentials of the spike receptor binding and N-terminal domains in addressing transmissibility and infectivity of SARS-CoV-2 variants of concern. <i>Journal of Infection</i> , 2022, 84, e62-e63.	1.7	17
132	Role of Lymphocyte Multidrug Resistance Protein 1 in HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 40, 257-266.	0.9	16
133	Improved Interpretation of Genotypic Changes in the HIV Reverse Transcriptase Coding Region That Determine the Virological Response to Didanosine. <i>Journal of Infectious Diseases</i> , 2007, 196, 1645-1653.	1.9	16
134	The Effect of Polymorphisms in Candidate Genes on the Long-Term Risk of Lipodystrophy and Dyslipidemia in HIV-Infected White Patients Starting Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2011, 27, 1299-1309.	0.5	16
135	Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. <i>Journal of Infection</i> , 2012, 65, 439-446.	1.7	16
136	Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment. <i>PLoS ONE</i> , 2016, 11, e0162320.	1.1	16
137	HIV-Associated Bacteremia: How It Has Changed in the Highly Active Antiretroviral Therapy (HAART) Era. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2000, 23, 145-151.	0.9	15
138	The Importance of Addressing Multidrug Resistance and Not Assuming Single-Drug Resistance in Case-Control Studies. <i>Infection Control and Hospital Epidemiology</i> , 2006, 27, 670-674.	1.0	15
139	The Threshold Bootstrap Clustering: A New Approach to Find Families or Transmission Clusters within Molecular Quasispecies. <i>PLoS ONE</i> , 2010, 5, e13619.	1.1	15
140	HIV INFECTION, ANTIRETROVIRAL THERAPY AND CARDIOVASCULAR RISK. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010034.	0.5	15
141	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). <i>International Journal of Epidemiology</i> , 2017, 46, dyv192.	0.9	15
142	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
143	Role of place of acquisition and inappropriate empirical antibiotic therapy on the outcome of extended-spectrum $\beta$ -lactamase-producing Enterobacteriaceae infections. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 49-54.	1.1	15
144	Dental care and HIV-infected individuals: are they equally treated?. <i>Community Dentistry and Oral Epidemiology</i> , 2005, 33, 447-453.	0.9	14

#	ARTICLE	IF	CITATIONS
145	Treatment of Skin and Soft Tissue Infections Due to Community-Associated Methicillin-Resistant Staphylococcus aureus in Europe: The Role of Trimethoprim-sulfamethoxazole. <i>Clinical Infectious Diseases</i> , 2011, 52, 1471-1472.	2.9	14
146	Economic evaluation of HIV treatments: The I.CO.N.A. cohort study. <i>Health Policy</i> , 2005, 74, 304-313.	1.4	13
147	Association of HIV-1 Replication Capacity With Treatment Outcomes in Patients With Virologic Treatment Failure. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 45, 411-417.	0.9	13
148	Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients. <i>Journal of Infection</i> , 2011, 62, 319-321.	1.7	13
149	Systematic clinical management of patients with candidemia improves survival. <i>Journal of Infection</i> , 2018, 77, 145-150.	1.7	13
150	Hydroxychloroquine and mortality in COVID-19 patients: a systematic review and a meta-analysis of observational studies and randomized controlled trials. <i>Pathogens and Global Health</i> , 2021, 115, 456-466.	1.0	13
151	Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey. <i>International Journal of Clinical Practice</i> , 2021, 75, e14755.	0.8	13
152	Hemangiomas and Other Congenital Malformations in Infants Exposed to Antiretroviral Therapy In Utero. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 305-305.	3.8	12
153	Response of Feline Immunodeficiency Virus (FIV) to Tipranavir May Provide New Clues for Development of Broad-Based Inhibitors of Retroviral Proteases Acting on Drug-Resistant HIV-1. <i>Current HIV Research</i> , 2008, 6, 306-317.	0.2	12
154	Prevalence, incidence and predictors of anal high-risk HPV infections and cytological abnormalities in HIV-infected individuals. <i>Journal of Infection</i> , 2015, 70, 60-71.	1.7	12
155	Antibodies against a $\beta$ -glucan-protein complex of <i>Candida albicans</i> and its potential as indicator of protective immunity in candidemic patients. <i>Scientific Reports</i> , 2017, 7, 2722.	1.6	12
156	Interpretation systems for genotypic drug resistance of HIV-1. <i>Scandinavian Journal of Infectious Diseases</i> , 2003, 35, 29-34.	1.5	11
157	Sphingosine 1-phosphate promotes antigen processing and presentation to CD4+ T cells in <i>Mycobacterium tuberculosis</i> -infected monocytes. <i>Biochemical and Biophysical Research Communications</i> , 2007, 361, 687-693.	1.0	11
158	Prospective evaluation of epidemiological, clinical, and microbiological features of pandemic influenza A (H1N1) virus infection in Italy. <i>Journal of Medical Virology</i> , 2011, 83, 2057-2065.	2.5	11
159	Bicyclic peptidomimetics targeting secreted aspartic protease 2 (SAP2) from <i>Candida albicans</i> reveal a constrained inhibitory chemotype. <i>Bioorganic and Medicinal Chemistry</i> , 2012, 20, 7206-7213.	1.4	11
160	Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance. <i>BMC Psychology</i> , 2013, 1, 3.	0.9	11
161	Baseline CD4 <sup>+</sup> T-cell Count and Cardiovascular Risk Factors Predict the Evolution of Cognitive Performance During 2-Year follow-up in HIV-Infected Patients. <i>Antiviral Therapy</i> , 2015, 20, 433-440.	0.6	11
162	A Murine, Bispecific Monoclonal Antibody Simultaneously Recognizing $\beta$ -Glucan and MP65 Determinants in <i>Candida</i> Species. <i>PLoS ONE</i> , 2016, 11, e0148714.	1.1	11

#	ARTICLE	IF	CITATIONS
163	Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. <i>Journal of Infection</i> , 2016, 73, 619-623.	1.7	11
164	Verbal list learning and memory profiles in HIV-infected adults, Alzheimer's disease, and Parkinson's disease: An evaluation of the "cortical hypothesis" of NeuroAIDS. <i>Applied Neuropsychology Adult</i> , 2017, 24, 410-419.	0.7	11
165	Performance evaluation of the (1,3)- $\beta$ -D-glucan detection assay in non-intensive care unit adult patients. <i>Infection and Drug Resistance</i> , 2019, Volume 12, 19-24.	1.1	11
166	Three-Year Clinical Outcomes of Resistance Genotyping and Expert Advice: Extended follow-up of the Argenta Trial. <i>Antiviral Therapy</i> , 2006, 11, 321-327.	0.6	11
167	A new, striking morphological alteration of P-glycoprotein expression in NK cells from AIDS patients. <i>Immunology Letters</i> , 1998, 60, 19-21.	1.1	10
168	Quinoline antimalarials as investigational drugs for HIV-1/AIDS: in vitro effects on HIV-1 replication, HIV-1 response to antiretroviral drugs, and intracellular antiretroviral drug concentrations. <i>Drug Development Research</i> , 2006, 67, 806-817.	1.4	10
169	Virological Suppression Reduces Clinical Progression in Patients with Multiclass-Resistant HIV Type 1. <i>AIDS Research and Human Retroviruses</i> , 2009, 25, 261-267.	0.5	10
170	Reduced soluble CD14 levels after switching from a dual regimen with lamivudine plus boosted protease inhibitors to lamivudine plus dolutegravir in virologically suppressed HIV-infected patients. <i>HIV Research and Clinical Practice</i> , 2019, 20, 92-98.	1.1	10
171	Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 1599-1603.	1.3	10
172	HIV Protease Inhibitors Prevent Mitochondrial Hyperpolarization and Redox Imbalance and Decrease Endogenous Uncoupler Protein-2 Expression in Gp120-Activated Human T Lymphocytes. <i>Antiviral Therapy</i> , 2005, 10, 29-45.	0.6	10
173	Age as a prognostic factor in AIDS. <i>Lancet, The</i> , 1996, 348, 623-624.	6.3	9
174	Risk scoring and bloodstream infections. <i>International Journal of Antimicrobial Agents</i> , 2007, 30, 88-92.	1.1	9
175	Variability of Raltegravir Plasma Levels in the Clinical Setting. <i>Pharmacology</i> , 2013, 92, 43-48.	0.9	9
176	3-Year Efficacy and Durability of Simplification to Single Tablet Regimens: A Comparison between Co-Formulated Efavirenz/Emtricitabine/Tenofovir and Rilpivirine/Emtricitabine/Tenofovir. <i>Antiviral Therapy</i> , 2018, 23, 139-148.	0.6	9
177	Expression of the Novel T Cell Activation Molecule hpH4 in HIV-Infected Patients: Correlation with Disease Status. <i>AIDS Research and Human Retroviruses</i> , 2000, 16, 549-557.	0.5	8
178	Nosocomial acquisition of methicillin-resistant <i>Staphylococcus aureus</i> (MRSA) and extended-spectrum beta-lactamase (ESBL) Enterobacteriaceae in hospitalised patients: a prospective multicenter study. <i>BMC Infectious Diseases</i> , 2012, 12, 74.	1.3	8
179	Resource-saving advice from an infectious diseases specialist team in a large university hospital: an exportable model?. <i>Future Microbiology</i> , 2015, 10, 15-20.	1.0	8
180	P-170 glycoprotein (P-170) is involved in the impairment of natural killer cell-mediated cytotoxicity in HIV+ patients. <i>Immunology Letters</i> , 1995, 47, 223-226.	1.1	7

#	ARTICLE	IF	CITATIONS
181	Bone mineral density improvement after 48 weeks of switch to maraviroc+darunavir/ritonavir 300/800/100 mg QD, preliminary results of GUSTA study. <i>Journal of the International AIDS Society</i> , 2014, 17, 19816.	1.2	7
182	Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre. <i>Journal of the International AIDS Society</i> , 2014, 17, 19817.	1.2	7
183	Evaluation of efficacy, pharmacokinetics and tolerability of peptidomimetic aspartic proteinase inhibitors as cream formulation in experimental vaginal candidiasis. <i>Journal of Pharmacy and Pharmacology</i> , 2014, 66, 1094-1101.	1.2	7
184	Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin. <i>Internal and Emergency Medicine</i> , 2017, 12, 1059-1067.	1.0	7
185	People Living with HIV in the COVID-19 Era: A Case Report. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 253-254.	0.5	7
186	Decreased function of Fas in patients displaying delayed progression of HIV-induced immune deficiency. <i>The Hematology Journal</i> , 2001, 2, 220-227.	2.0	7
187	Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): a randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 398-410.	1.3	6
188	Differential induction of P-glycoprotein and MRP by rifamycins in T lymphocytes from HIV-1/tuberculosis co-infected patients. <i>Aids</i> , 2002, 16, 1563-1565.	1.0	6
189	Generic antiretrovirals for the treatment of HIV: a novel challenge for Western countries?. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017, 55, 381-393.	0.3	6
190	Attitudes and practices of dentists treating patients infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. <i>Medical Science Monitor</i> , 2009, 15, PH49-56.	0.5	6
191	The SARS-CoV-2 Mu variant should not be left aside: It warrants attention for its immunoevading ability. <i>Journal of Medical Virology</i> , 2022, 94, 2479-2486.	2.5	6
192	Evaluation of the antiretroviral effects of a PEG-conjugated peptide derived from human CD38. <i>Expert Opinion on Therapeutic Targets</i> , 2009, 13, 141-152.	1.5	5
193	Liver fibrosis is associated with cognitive impairment in HIV-positive patients. <i>Journal of the International AIDS Society</i> , 2014, 17, 19722.	1.2	5
194	Safety of darunavir/ritonavir (DRV/r) in HIV-1-infected DRV/r-experienced and -naïve patients: analysis of data in the real-world setting in Italy. <i>Journal of the International AIDS Society</i> , 2014, 17, 19573.	1.2	5
195	Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection. <i>Infectious Diseases</i> , 2016, 48, 48-55.	1.4	5
196	Evaluation and Optimization of an ELISA Procedure to Quantify Antibodies Against Pneumococcal Polysaccharides Included in the 13-Valent Conjugate Vaccine. <i>Journal of Immunoassay and Immunochemistry</i> , 2016, 37, 189-200.	0.5	5
197	Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients. <i>Journal of Chemotherapy</i> , 2017, 29, 299-307.	0.7	5
198	Shortening Epitopes to Survive: The Case of SARS-CoV-2 Lambda Variant. <i>Biomolecules</i> , 2021, 11, 1494.	1.8	5

#	ARTICLE	IF	CITATIONS
199	Liver fibrosis is associated with cognitive impairment in people living with HIV. <i>Infection</i> , 2019, 47, 589-593.	2.3	4
200	Recurrent venous thrombosis in a patient with haemophilia A and HIV infection. <i>Haematologica</i> , 2002, 87, ECR04.	1.7	4
201	Effects of Antiretroviral Therapy on Tube-Like Network Formation of Human Endothelial Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2007, 30, 982-984.	0.6	3
202	High rate of Quantiferon positive and tuberculin negative tests in infants born at a large Italian University Hospital in 2011: a cautionary hypothesis. <i>Pathogens and Global Health</i> , 2012, 106, 8-11.	1.0	3
203	Is There a Drug-Drug Interaction Between Darunavir/Ritonavir and Raltegravir?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, e18-e20.	0.9	3
204	Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3621-3622.	1.3	3
205	Antibiotic stewardship from toolkit to local implementation: the "gutta cavat lapidem" strategy. <i>Future Microbiology</i> , 2017, 12, 935-938.	1.0	3
206	Knowing more about chloroquine/hydroxychloroquine in COVID-19 patients. <i>Future Microbiology</i> , 2020, 15, 1523-1526.	1.0	3
207	A call to research: the relationship between SARS-2-CoV, ACE 2 and antihypertensives. <i>Pathogens and Global Health</i> , 2020, 114, 165-167.	1.0	3
208	International infectious diseases teaching to undergraduate medical students: A successful European collaborative experience. <i>Medical Teacher</i> , 2017, 39, 981-986.	1.0	3
209	Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. <i>AIDS Reviews</i> , 2005, 7, 161-7.	0.5	3
210	Cognitive impairment and cardiovascular disease related to alexithymia in a well-controlled HIV-infected population. <i>Infezioni in Medicina</i> , 2019, 27, 274-282.	0.7	3
211	Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey. <i>Infezioni in Medicina</i> , 2021, 29, 54-64.	0.7	3
212	Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction?. <i>Antiviral Therapy</i> , 2009, 14, 99-101.	0.6	3
213	Antiapoptotic Activity by HIV Protease Inhibitors either Alone or Boosted. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2002, 31, 545-546.	0.9	2
214	Long-Term Serological Response to 13-Valent Pneumococcal Conjugate Vaccine Versus 23-Valent Polysaccharide Vaccine in HIV-Infected Adults. <i>Infectious Diseases and Therapy</i> , 2019, 8, 453-462.	1.8	2
215	Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. <i>Journal of Healthcare Engineering</i> , 2021, 2021, 1-10.	1.1	2
216	Ophthalmic artery resistance index is increased in HIV-Infected patients and is influenced by protease inhibitors exposure. <i>Journal of Infection</i> , 2014, 68, 500-503.	1.7	1

#	ARTICLE	IF	CITATIONS
217	A pilot experience of common European infectious diseases curriculum for medical students: the IDEAL summer school. <i>Future Microbiology</i> , 2019, 14, 369-372.	1.0	1
218	Day 10 Post-Prescription Audit Optimizes Antibiotic Therapy in Patients with Bloodstream Infections. <i>Antibiotics</i> , 2020, 9, 437.	1.5	1
219	Gene Xpert MTB/RIF assay confirms its value in the first multicentre, randomised, controlled trial conducted in primary-care settings in Africa. <i>Pathogens and Global Health</i> , 2014, 108, 127-127.	1.0	0
220	Electronic Prescribing. , 2008, , 41-67.		0